Yes, belumosudil (Rezurock) is FDA approved. The U.S. Food and Drug Administration (FDA) approved belumosudil on July 16, 2021. This approval was granted based on the drug’s efficacy in treating chronic GVHD in patients who have not responded to at least two prior lines of systemic therapy.
Belumosudil is specifically used to manage chronic graft-versus-host disease (GVHD) in both adults and children aged 12 years and older. GVHD is a condition that can occur after an allogeneic stem cell transplant, where the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body.
Belumosudil is available as a 200 mg oral tablet and is typically taken once a day with a meal. It is crucial to follow the prescription instructions carefully:
Patients are advised to take the medication with a full glass of water at the same time each day. The tablets should be swallowed whole and not crushed, chewed, or broken.
Common side effects of belumosudil may include:
Serious side effects that require immediate medical attention include:
Patients should not use belumosudil if they are allergic to it or have liver or kidney problems. Women of childbearing potential should use effective birth control during treatment and for at least one week after the last dose, as belumosudil can harm an unborn baby. Breastfeeding is not recommended while using this medication and for at least one week after the last dose.
Belumosudil (Rezurock) is an FDA-approved medication effective in managing chronic graft-versus-host disease in patients who have not responded to previous treatments. Patients prescribed this medication should follow their doctor’s instructions carefully and be aware of potential side effects and necessary precautions.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!